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Objectives The purpose of this study was to assess the association between structural changes in human atria, age, and
history of atrial fibrillation (AF).
Background Development of fibrosis in atrial walls is associated with deterioration of atrial conduction and predisposes to AF
in experiment. Human data, however, are scarce, and whether fibrosis is a cause or consequence of AF is not
known.
Methods Medical records for consecutive autopsies were checked for AF history and duration. Atrial specimens from
30 patients (ages 64  12 years) were collected in 3 equal age-matched groups as patients without AF history,
with paroxysmal AF, or with permanent AF. Tissue samples were obtained at the level of superior pulmonary
veins, inferior pulmonary veins, center of posterior left atrial wall, terminal crest, and Bachmann’s bundle. Histol-
ogy sections were assessed for extent of fibrosis, fatty tissues, and inflammatory infiltration at each location.
Results No correlation was observed between age and fibrosis at any location. Fibrosis extent and fatty infiltration were
twofold to threefold higher at all locations in patients with history of AF and correlated with lymphomononuclear
infiltration. Patients with permanent AF had greater fibrosis extent than did patients with paroxysmal AF.
Conclusions In post-mortem material, structural changes in the atria were not associated with age, but were significantly cor-
related with presence of AF and its severity. Our findings suggest that age-related changes per se are unlikely to
be the sole cause of advanced fibrosis underlying AF. (J Am Coll Cardiol 2011;58:2225–32) © 2011 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.05.061Structural atrial remodeling is a well-described phenome-
non in patients with atrial fibrillation (AF). Alterations in
atrial structure and function associated with AF are com-
monly expressed as left atrial enlargement and reduced
contractility that are likely to be caused by cardiomyocyte
and interstitial changes observed in animal models of AF
(1,2). Whether fibrotic transformation of atrial myocardium
is a cause or consequence of AF in patients with cardiovas-
cular disease remains a matter of debate. Aging is associated
with the risk of developing AF, which has commonly been
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accepted May 24, 2011.explained by the age-dependent change in cellular electro-
physiological properties shown in experiment (3) as well as
loss and isolation of atrial myocardium and associated atrial
conduction disturbances predisposing to AF (4).
Recent developments in magnetic resonance imaging
resulted in the development of methodology aimed at
detecting the presence of atrial fibrosis with delayed en-
hancement by using extracellular gadolinium-based contrast
agents (5). Using this technique, the presence and extent of
atrial fibrosis showed an association with AF persistency (6)
See page 2233
and is similar in AF patients regardless of any comorbidities,
thus suggesting a close pathophysiological link between
atrial fibrosis and arrhythmogenesis (7). However, human
histology data that would prove the validity of this concept
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Atrial Fibrosis in Atrial Fibrillation November 15, 2011:2225–32mostly patients with mitral valve
disease (8). A single report (9) on
patients with lone AF reported
an association between the pres-
ence of fibrosis and the history of
AF. Although the association
between age, atrial fibrosis ex-
tent, and development of post-
operative AF has been reported
in patients undergoing open-
heart surgery in several studies
(10 –12), those investigations
were based on the atrial append-
age tissue samples. A systematic
qualitative and quantitative study
of atrial tissues from both cham-
bers of nonvalvular AF is lacking.
In this study, we analyzed the
extent of histological abnormalities in the left atrium (LA)
and major atrial conduction routes to elucidate any correla-
tion between the presence and clinical types of AF, age, and
comorbidities.
Methods
Study design. After local ethics approval for medical re-
search, 276 autopsies at the Federal Heart, Blood, and
Endocrinology Centre (St. Petersburg, Russia) from January
1, 2009, to June 15, 2010, were reviewed. To minimize
selection bias impact, medical records of consecutive cases of
in-hospital deaths referred for post-mortem studies were
screened for AF presence and clinical type. Patients with AF
after open-heart surgery were excluded. We compared 3
Abbreviations
and Acronyms
AF  atrial fibrillation
BB  Bachmann’s bundle
CT  crista terminalis
IPV  inferior pulmonary
vein
LA  left atrium
PermAF  permanent atrial
fibrillation
PLA  posterior left atrial
wall
PxAF  paroxysmal atrial
fibrillation
SPV  superior pulmonary
vein
Figure 1 Tissue Sampling Locations
Locations of tissue sample collection (red stars) from crista terminalis at lateral r
tions between superior pulmonary veins (SPV), inferior pulmonary veins (IPV), andgroups of 10 subjects each, all without significant valvular
disease: no indication of AF history (NoAF group); history
of paroxysmal or repeatedly cardioverted persistent AF
(PxAF group); and history of permanent AF with duration
of at least 1 year before death (PermAF group).
Tissue sample collection and handling. Transmural atrial
tissue samples of at least 20 mm  3 mm were collected
from 5 locations that included major atrial conduction
pathways and posterior LA region in the vicinity of pulmo-
nary vein ostia (Fig. 1). The sites were as follows: crista
terminalis (CT) at right atrium lateral wall; Bachmann’s
bundle (BB) from the superior portion of the interatrial
groove between the atria; posterior LA wall at superior
pulmonary vein (SPV) level; centrally between pulmonary
vein ostia (posterior left atrial [PLA] wall); and at inferior
pulmonary veins (IPV) level.
Atrial tissue samples were fixed in 10% buffered formalin
and embedded in paraffin. Sections (2 m thick) were cut
arallel to the atrial wall plane and stained with Masson’s
richrome stain (Fig. 2).
Specimens were examined with computer-assisted mor-
hometric analysis using the Leica LAS Image Analysis
ystem (LeicaQWin Plus v3, Leica Microsystems Imaging
olutions, Cambridge, United Kingdom).The percentage of
atty infiltration, interstitial fibrosis, capillary density, and
ean cardiomyocyte diameter from within each sample
ere assessed at 200 magnification and calculated at 10
elds of view by a single investigator blinded to clinical and
emographic data. Epicardial, endocardial, and perivascular
brosis were excluded in assessing fibrosis percentage. A
ean of the 10 measurements for each parameter per
ocation was used for further analysis.
rium (CT), Bachmann’s bundle (BB), and posterior left atrial wall (PLA) at 3 loca-
center of PLA. LA  left atrium; RA  right atrium.ight at
in the
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November 15, 2011:2225–32 Atrial Fibrosis in Atrial FibrillationMyocardial infiltration of inflammatory cells was exam-
ined histologically using polyclonal rabbit anti-human an-
tibodies to CD3 pan-T cellular antigen (Dako Denmark
A/S, Glostrup, Denmark) and monoclonal mouse anti-
human antibodies to CD45 leukocyte common antigen
clone 2B11  PD7/26 (Dako Denmark A/S). Immuno-
staining was carried out in 3 samples taken at CT, BB, and
PLA. Inflammatory cell count was performed separately for
CD3-positive and CD45-positive cells at 200 magnifica-
tion and calculated as a mean cell count per 1 mm2 at 10
fields of view at each location.
Statistical analyses. Data are expressed as the mean  SD
unless stated otherwise. All statistical analyses were per-
formed using IBM SPSS Statistics, version 19.0.0 (SPSS,
Chicago, Illinois). An independent-samples (Kruskal-
Wallis) test was used for comparing continuous variables
among the 3 patient groups. The Mann-Whitney test was
used for 2-group comparisons. No correction for multiple
testing was applied. Spearman’s correlation coefficient was
calculated for analyzing correlation between quantified his-
tological variables and clinical characteristics. All tests were
2 sided, and p 0.05 was considered statistically significant.
Results
Patient characteristics. Clinical characteristics of patients
are presented in Table 1. Median age was 62 years (range 39
to 86 years). The majority of patients died of cardiovascular
causes such as acute myocardial infarction (n  20), stroke
(n  1), and pulmonary embolism (n  7). Two patients
died of pneumonia.
Patients without a history of AF were older than patients
with any history of AF (68  10 years vs. 62  13 years)
and had an over-representation of men (8 of 10 vs. 9 of 20);
however, these differences did not reach statistical signifi-
cance. There was no difference in regard to the presence of
Figure 2 Fibrosis Extent in Atrial Walls
Light microscopy of crista terminalis specimens in patients with (A) permanent at
(A) Fibrosis extent 51%, fat 15%, capillary density 2%, mean cardiomyocyte diame
cyte diameter 11 m. (C) Fibrosis extent 5%, fat 1%, capillary density 1%, mean cardischemic heart disease, hypertension, stroke, chronic ob-structive pulmonary disease, diabetes mellitus, or aortic or
mitral valve pathology between patients with AF history and
without AF history. Comorbidity status expressed in
CHA2DS2-VASc score was 3.8 1.8 in AF patients versus
.3  1.9 in patients without AF (p  0.05). CHADS2
score was 2.6  1.3 versus 2.8  1.2 in AF and non-AF
patients, respectively (p  0.7).
illation (AF), (B) paroxysmal atrial fibrillation, and (C) without history of AF.
m. (B) Fibrosis extent 14%, fat 24%, capillary density 0.4%, mean cardiomyo-
yte diameter 15 m. (Masson’s trichrome stain; original magnification 200.)









Age, yrs 68 10 62 10 61 15
Male 8 4 5
BMI, kg/m2 26.4 7.1 28.7 6.8 23.4 6.8
Left atrial diameter, mm 40 5 48 8 56 13*
LVEF, % 39 15 40 19 41 7
QRS 120 ms 3 5 1
Comorbidities
Ischemic heart disease 10 7 9
CHF 10 9 10
Hypertension 8 9 8
Diabetes mellitus 3 1 4
Stroke 3 2 3
COPD 4 2 0
CHA2DS2-VASc score 4.3 1.9 3.3 1.5 4.3 1.9
CHADS2 score 2.8 1.2 2.4 1.2 2.9 1.4
Pharmacological therapy
ACEI or ARB 10 8 10
Statins 6 3 3
Amiodarone 0 3 3
Beta-blockers 8 9 10
Digoxin 1 0 6†
Values are mean  SD or n. *p  0.026 in comparison with no atrial fibrillation (AF) group. †p 
0.004 in comparison with no AF and paroxysmal AF groups.
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin-2 receptor blocker; BMI rial fibr
ter 12
iomyocbody mass index; COPD  chronic obstructive pulmonary disease; LVEDD  left ventricular
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Atrial Fibrosis in Atrial Fibrillation November 15, 2011:2225–32There was no difference between the groups in regard to
pharmacological treatment with angiotensin-converting en-
zyme inhibitors, angiotensin-2 receptor blockers, beta-
blockers, statins, or diuretics. Digoxin was commonly used
in PermAF patients but not in the NoAF or PxAF groups
(Table 1).
Echocardiographic data were available for 21 patients
(16 AF and 5 NoAF patients) and concerned examina-
tions performed during these patients’ last hospital ad-
mission. The LA diameter measured in parasternal view
was significantly larger in patients with AF history (52 
11 mm vs. 40  5 mm, p  0.039) while there was no
ifference in left ventricular ejection fraction (39  15%
s. 40  14%, p  0.802).
Medical record information on AF history duration
median 24 months, range 0.5 to 192 months) was available
or 18 patients. The remaining 2 patients presented with
xAF with unknown time of symptom onset.
ite-dependent histological abnormalities. The extent of
brosis, fatty infiltration, capillary density, and cardiomyo-
yte size did not differ among the 5 sampling locations in
he atria, neither in total material nor in subgroup analysis
data not shown).
Possible correlation between fibrosis and any other his-
ological variable was assessed at all 5 locations. The extent
f fibrosis demonstrated weak positive correlation with the
ean cardiomyocyte diameter at BB (r 0.589, p 0.001),
PV (r  0.459, p  0.011), and PLA (r  0.453, p 
.012) locations. We observed no significant correlation
etween the extent of fibrosis and capillary density at any
ocation. In PLA, the extent of fibrosis showed significant
ositive correlation with the extent of fatty infiltration (r 
.439, p  0.015), but at all other locations, no such
ssociation was observed (data not shown).
The extent of fibrosis positively correlated with CD3-
ositive and CD45-positive leukocyte count at BB (r 
.75, p  0.001 for CD3; and r  0.67, p  0.001 for
D45) and PLA (r  0.76, p  0.001 for CD3; and r 
.67, p  0.001 for CD45), but not at CT.
trial fibrillation history. Patients with any history of AF
ad a 3- to 5-fold greater extent of fibrosis and fatty tissue
ompared to patients without AF history, regardless of
issue sampling location (Table 2). Similarly, a strong
ssociation between inflammatory cell count and AF history
as observed at all tissue sampling locations where inflam-
atory response was assessed (Table 3). However, neither
apillary density nor mean cardiomyocyte diameter showed
ny notable difference among the groups in regard to the AF
istory.
A 3-group comparison revealed generally greater extent
f fibrosis in PermAF patients compared with PxAF pa-
ients, and passed the significance threshold for BB and
PV locations (Fig. 3). This phenomenon, however, was
ot observed when the extent of fatty tissue was compared.
The extent of fibrosis alone showed borderline signifi-ance for correlation with AF history duration at IPV (r  d.466, p 0.05) (Fig. 4), but not at any other location. The
orrelation of combined count for fibrosis and fatty infiltra-
ion and AF history duration at IPV was stronger than for
brosis alone (r  0.675, p  0.002) (Fig. 4). The AF
istory duration also showed positive correlation with car-
iomyocyte diameter that reached significance at BB loca-
ion (r  0.542, p  0.02).
eft atrial diameter. Left atrial diameter strongly corre-
ated with the extent of fibrosis at all LA locations, IPV (r
.548, p  0.01), PLA (r  0.574, p  0.006), and SPV
r  0.687, p  0.001), whereas fatty infiltration showed
ositive correlation with LA diameter at BB (r 0.490, p
.024), CT (r  0.496, p  0.026), and PLA (r  0.502,
 0.02). Combined fibrosis and fatty tissue count corre-
ated with LA diameter at all 5 locations: CT (r  0.504,
 0.020), BB (r 0.610, p 0.003), IPV (r 0.618, p
.003), PLA (r  0.634, p  0.002), and SPV (r  0.598,
 0.004). Neither capillary density nor mean cardiomyocyte











Crista terminalis 23 19 20 14 8 5 28 15†
Bachmann’s bundle 21 16 18 14 8 4 25 14†
Inferior PV 28 23 13 10 5 3 26 18†
Posterior LA 26 17 14 11* 6 3 25 13†
Superior PV 23 16 14 10 7 5 22 13†
Fatty tissue, %
Crista terminalis 8 7 9 10 3 5 12 10‡
Bachmann’s bundle 13 13 7 4 4 4 13 10‡
Inferior PV 10 11 7 7 4 4 8 5*
Posterior LA 7 5 6 5 3 3 8 5‡
Superior PV 9 11 9 9 4 3 12 10‡
Fibrosis and fatty tissue, %
Crista terminalis 32 22 29 18 12 7 40 17†
Bachmann’s bundle 34 19 26 17 11 5 38 16†
Inferior PV 37 26 20 15 9 5 35 20†
Posterior LA 33 20 20 13 8 4 33 15†
Superior PV 32 18 23 15 11 4 34 15†
Capillary density, %
Crista terminalis 1.6 1.0 1.5 0.7 1.2 0.7 1.4 0.8
Bachmann’s bundle 2.5 1.4 1.8 1.9 2.4 2.5 1.9 1.3
Inferior PV 2.9 1.2 1.8 2.5 2.9 3.3 1.8 1.4
Posterior LA 1.8 0.8 1.6 1.2 2.0 1.0 1.6 1.0
Superior PV 1.6 0.9 2.2 2.4 1.0 0.3 2.0 2.4
Cardiomyocyte diameter, m
Crista terminalis 20 4 18 4 18 4 19 4
Bachmann’s bundle 20 8 20 4 18 4 21 6
Inferior PV 20 5 19 3 17 3 20 4
Posterior LA 19 5 20 4 18 3 20 5
Superior PV 21 4 19 4 19 3 20 4
Values are mean  SD. *p  0.05; †p  0.01; ‡p  0.001.









2229JACC Vol. 58, No. 21, 2011 Platonov et al.
November 15, 2011:2225–32 Atrial Fibrosis in Atrial FibrillationThe CD3-positive cell count demonstrated positive cor-
relation with LA diameter at all tissue sampling locations:
r  0.45, 0.50, and 0.47 for CT, BB, and PLA, respectively
(all p  0.05). The CD45-positive cell count correlated
with LA diameter at CT and BB (r  0.46 and 0.47,
respectively, p  0.05 for both), but not at PLA.
Age and sex. No sex-related associations were observed for
ny histology parameter. No increase in atrial fibrosis
ssociated with higher age was observed either in total
aterial or in patient subgroups with or without AF history
Fig. 3). None of the histology parameters, including
brosis, showed any significant correlation with age in
ither subgroups or total material (data not shown) using
pearman’s correlation.





Crista terminalis 10.6 4.4
Bachmann’s bundle 9.3 4.5
Posterior left atrial wall 9.8 4.5
CD3 cell count
Crista terminalis 7.6 4.4
Bachmann’s bundle 5.2 3.2
Posterior left atrial wall 4.2 2.0
Values are mean  SD. *p  0.05; †p  0.01; ‡p  0.001 in compa
Figure 3 Fibrosis Extent, Age, and Clinical Type of AF
Association between fibrosis extent, age (upper panels) and atrial fibrillation (AF)
circles  paroxysmal AF; green circles  no AF. The extent of fibrosis is significa
the box plots correspond to ranges in the data series. LA  left atrium; PV  pulmDiscussion
Our study, carried out in a systematic fashion, provides
histological evidence of a robust association between extent of
structural changes in left atrial walls and major atrial conduc-
tion pathways with AF history and clinical type. Patients with
permanent AF consistently had more extensive fibrofatty
replacement of atrial myocardium than patients with paroxys-
mal AF and otherwise similar clinical profile. On the contrary,
despite the wide age range and the presence of comorbidities
likely to contribute to fibrosis development in all 3 groups, we
were not able to detect any correlation between patient age and
increase in the extent of fibrosis or fatty changes in atrial tissue,
in either total material or subgroup analyses.
dut AF Historyathway and







6.9* 25.7 7.3‡ 24.6 7.0‡
4.1† 28.8 11.4‡ 24.8 9.3‡
3.8* 25.6 6.9‡ 22.7 6.2‡
7.8* 24.4 7.5‡ 21.8 7.9‡
6.2† 27.3 11.9‡ 21.9 10.7‡
5.4† 25.1 8.6‡ 19.9 8.8‡
ith no atrial fibrillation (AF) group.
ower panels) at all tissue sampling locations. Red circles  permanent AF; blue
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Atrial Fibrosis in Atrial Fibrillation November 15, 2011:2225–32Previous studies. Human data on association between the
extent of structural atrial changes and the presence of lone
AF are scarce. In 1 study (9), the presence of patchy fibrosis
along with widespread inflammatory changes was observed
in atrial septal biopsies taken from patients with lone AF
but not in patients without AF history. However, it was
unclear whether AF in patients with cardiovascular disease
would demonstrate a similarly strong association between
fibrosis and arrhythmia or whether structural abnormalities
confined to the atrial septum were also present in other parts
of atria. Our study of nonvalvular AF in patients with
comorbidities commonly associated with development of
AF, namely, mainly ischemic heart disease and hyperten-
sion, is relevant to the vast majority of AF patients seen in
clinical practice.
Absolute values of fibrosis extent observed in the NoAF
group are in the same range as those reported in right atrial
appendage biopsies collected from patients without AF
history during open-heart surgery using similar fibrosis
quantification techniques (10,11,13). Swartz et al. (11)
examined tissue samples from right and left atrial append-
ages collected from 44 patients without prior AF history
during open-heart surgery and reported 10.8 11% fibrosis
xtent in patients who had post-operative AF compared
ith 3.8  3.5% in patients remaining in normal sinus
hythm. The authors also reported more fibrosis in left
trium compared with right atrium, but that finding is not
upported by our study. In a study by Goette et al. (10),
brosis extent in right atrial appendage was significantly
ssociated with both age and AF incidence in the post-
perative period, thus supporting the causative role of
ge-related fibrosis in post-operative AF. The discrepancy
an be explained by significant differences between post-
perative AF in the study by Swartz et al. (11), whereas AF
as remote from open-heart surgery in our cases.
Figure 4 Association Between Fibrosis, Fat, and Duration of AF
Extent of fibrosis (left) and combined fibrosis and fat (right) in the vicinity of infer
positive correlation with atrial fibrillation (AF) history duration. Blue circles  paroOur finding of a strong association between fibrosis
xtent and inflammatory cell count in patients with AF
istory is in agreement with earlier reports (14,15), and
urther supports the important role inflammation plays in
reation of an AF substrate. We demonstrated the presence
f inflammatory infiltrate in major atrial pathways (CT and
B) and in posterior LA wall in patients with AF, and
ocumented its association with LA dilation.
ibrosis in AF: cause or consequence? Recent develop-
ents in imaging and the introduction of delayed-
nhancement technology provided indirect evidence of fi-
rosis in the left atrium associated with the presence of AF
egardless of comorbidities (7). In another study, delayed-
nhancement magnetic resonance imaging revealed that
atients with persistent AF compared with paroxysmal AF
howed more fibrosis in the left atrium (16). Our study is in
greement with these observations and provides direct
istological evidence of the pathophysiological association
etween extent of fibrofatty atrial abnormalities and AF
resence and persistency.
Our study results, however, do not answer the question of
hether the fibrofatty replacement of atrial myocardium
ssociated with AF presence is the cause or the consequence
f the arrhythmia. The observed structural alterations in the
atients in our study could have developed as a result of
ore or less long-standing AF, and, if so, the changes we
bserved truly represent structural atrial remodeling. How-
ver, fibrosis may have occurred secondary to an unknown
actor such as an inflammatory process in the atrial myo-
ardium or an inherited predisposition to fibrosis develop-
ent. Numerous observations of increased inflammatory
tate markers in patients with AF (17) and our findings of
he close link between fibrosis extent and lymphomononu-
lear infiltration support this hypothesis. Several genetic loci
ssociated with AF have been reported recently in large-
ory
monary veins (PV) demonstrate
l AF; red circles  permanent AF.Hist
ior pul
xysma
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November 15, 2011:2225–32 Atrial Fibrosis in Atrial Fibrillationscale epidemiological studies; however, their relation to the
development of fibrosis is not yet known (18–20).
Experimental data comparing AF promoted by rapid
atrial pacing and the development of congestive heart failure
in dogs suggest that atrial pacing-induced AF in the absence
of congestive heart failure per se does not promote devel-
opment of fibrosis (1). Our findings in humans contradict
these experimental data. First, we were not able to detect
any link between the extent of fibrosis and left ventricular
ejection fraction, whereas the significant association be-
tween LA size and structural abnormalities mostly confined
to LA was rather an expected finding. Second, atrial samples
taken from age-matched arrhythmia-free patients contained
negligibly low amounts of fibrofatty tissue despite similar
clinical profile and the presence of congestive heart failure,
ischemic heart disease, or hypertension in the majority of
subjects in all 3 groups. It cannot be completely ruled out
that patients without AF history in our study had less severe
clinical manifestations of accompanying conditions, leading
to less advanced atrial structural changes that could not be
reliably evaluated in a retrospective journal-based analysis.
Nevertheless, patients with permanent AF in our study had
significantly more extensive structural atrial abnormalities
than did patients with paroxysmal AF associated with AF
history duration.
Structural abnormalities of major conduction pathways.
We have demonstrated not only the presence of fibrofatty
replacement of atrial myocardium in the LA recently linked
to the effect of catheter ablation (7), but we also analyzed
the extent of structural abnormalities in major atrial con-
duction pathways, namely, BB and CT. Deteriorated atrial
conduction in patients with paroxysmal AF has been well
documented in electrocardiographic (21,22) and invasive
electrophysiological studies (23,24). In a recent study of
patients enrolled in the MADIT-II (Multicenter Automatic
Defibrillator Implantation Trial II), we have shown that
abnormal atrial conduction bears an independent predictive
value for developing new-onset AF in patients with
ischemic heart failure, thus supporting the primary role of
conduction defects in developing AF in this patient
population (25). Although the possibility of strategically
located structural atrial abnormalities affecting the BB
and terminal crest was reported in an earlier study by
Becker et al. (26) on both valvular and nonvalvular AF, our
study provides a morphometric analysis of these changes
and suggests that the changes are likely to represent a
manifestation of a generalized pathological process affecting
the LA and right atrium equally.
Lack of age-related increase in extent of structural
changes. Although an association between age and atrial
fibrosis has become conventional wisdom, and “age-related
fibrosis” is listed as 1 of the etiological factors underlying AF
development in management guidelines (4), analyses of
atrial wall histology, with few exceptions (8,9), were mostly
performed on patients undergoing open-heart surgery with-
out prior history of AF (10,11,13). Prevalence of AF hasbeen clearly shown to increase with age (27,28); however,
whether the increase was due to extensive atrial fibrosis has
not been convincingly demonstrated. In a recent report,
right atrial appendage biopsies taken during open-heart
surgery in patients without AF history revealed positive
correlation between fibrosis extent and age (13). Our study
found no such correlation in a similar age span (although
smaller) population, suggesting that age-related increase in
fibrosis extent does not reach the magnitude of changes
observed in AF. We propose that age contribution to fibrosis
development is limited and unlikely to be the sole explanation
of the advanced fibrosis observed in AF patients.
Study limitations. We had to rely on medical record data
without the possibility of additional investigations to resolve
uncertainties or verify AF diagnosis. For the same reason,
echocardiographic variables are limited to left ventricular
ejection fraction and LA diameter as other measurements
relevant in the context of atrial remodeling, including left
ventricular diastolic function assessment, were not consis-
tently reported for all subjects. Finally, the small number of
cases might lead to possible underestimation of age effect on
structural changes of atrial walls, but we believe our detailed
histological analysis could mitigate that.
Conclusions
In post-mortem atrial tissues from patients who died of
cardiovascular causes, the extent of fibrosis was not associ-
ated with age, but was significantly correlated with AF
presence, severity, and duration. Chronic inflammation in
atrial myocardium is likely to play an important role this
process. Our findings suggest that age-related changes per
se are unlikely to be the sole cause of advanced fibrosis
underlying AF.
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